Pyxis Oncology (NASDAQ:PYXS) Stock Price Target Raised at Royal Bank Of Canada

Pyxis Oncology (NASDAQ:PYXS) had its price target raised by Royal Bank Of Canada from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also recently weighed in on PYXS. Wells Fargo & Company upped their price target on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Wedbush reduced their target price on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus set a $5.00 price target on Pyxis Oncology in a report on Thursday. Finally, HC Wainwright boosted their price target on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.71.

Pyxis Oncology Stock Up 3.1%

Pyxis Oncology stock traded up $0.05 during mid-day trading on Friday, hitting $1.66. 557,636 shares of the company’s stock were exchanged, compared to its average volume of 874,187. The company’s 50 day simple moving average is $2.51 and its 200-day simple moving average is $2.16. The firm has a market capitalization of $138.46 million, a P/E ratio of -1.28 and a beta of 1.41. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. Research analysts expect that Pyxis Oncology will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently modified their holdings of the stock. T3 Companies LLC bought a new stake in Pyxis Oncology during the third quarter worth about $61,000. Commonwealth Equity Services LLC grew its stake in Pyxis Oncology by 14.8% in the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after purchasing an additional 6,295 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares during the last quarter. Institutional investors own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.